sGC had been developing a new class of therapeutic drugs for treatment of Alzheimers Disease and age-related cognitive disorders anchored in work undertaken by one of the firm's principals at College of Pharmacy,University of Illinois, Chicago. sGC Pharma ceased operation on/around 2016 and the project - with the same PI transferred to North Carolina firm Revivo Therapeutics founded that same year and not (to date) an SBIR-STTR involved entity in their own right. T